Clinical Trials Directory

Trials / Completed

CompletedNCT02534701

ERic Acute StrokE Recanalization (ERASER)

Status
Completed
Phase
Study type
Observational
Enrollment
53 (actual)
Sponsor
Universitätsklinikum Hamburg-Eppendorf · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To monitor the effect of the ERIC® device in combination with SOFIA™ Distal Access Catheter on artery recanalization and on clinical outcomes in stroke patients using data from clinical routine application (ERASER). To additionally evaluate the effect of the ERIC® device in combination with SOFIA™ Distal Access Catheter on the final infarct volume as determined by advanced image postprocessing methods in the subgroup of patients with acute middle cerebral artery stroke (ERASER+).

Detailed description

This is a prospective, international, single-arm, controlled, open label post-market, multicenter study to compare the safety and effectiveness of ERIC® device in combination with SOFIA™ Distal Access Catheter in acute ischemic stroke patients using clinical routine data. Patients who meet the imaging inclusion criteria for ERASER will be included in the cohort where collected and additionally analyzed data will be compared to a historical patient cohort (referred to as ERASER imaging =ERASER+). All other patients will be included in a registry (referred to as ERASER), where clinical information will be collected. The overall study duration is expected to be 18 Months. The expected duration of each subject's enrolment is approximately 90 days. Subjects will be followed with assessments at 90 days post stroke. The basic concept of ERASER+ is the use an infarct prediction algorithm that has been trained on a large dataset of historical imaging data of patients treated with IV tPA, apply it to the pre-treatment imaging and compare its predictions with the actual outcome.

Conditions

Interventions

TypeNameDescription
DEVICEERIC® and SOFIA™a self-expanding clot retrieval system

Timeline

Start date
2015-05-01
Primary completion
2017-04-01
Completion
2017-07-01
First posted
2015-08-28
Last updated
2017-10-10

Locations

9 sites across 2 countries: Germany, Switzerland

Source: ClinicalTrials.gov record NCT02534701. Inclusion in this directory is not an endorsement.